Physician profile
Brian W Moore
NPI 1346402575
$9,748.61
in general payments reported to CMS, 2019-2025
36 companies · $4,069 in 2025
The $4,069 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $193 · 2021: $248 · 2022: $283 · 2023: $912 · 2024: $3,238 · 2025: $4,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,836 · Education: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,836.26 |
| Education | $382.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,340.91 | 2019-2025 | |
| Janssen Biotech, INC. | $1,255.94 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Incyte Corporation | $924.51 | 2023-2025 | Opzelura, Opzelura |
| Ucb, INC. | $824.25 | 2019-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $744.33 | 2023-2024 | Vtama |
| Lilly USA, LLC | $630.52 | 2019-2025 | Taltz, Ebglyss |
| Genzyme Corporation | $612.25 | 2019-2025 | |
| Galderma Laboratories, L.P. | $589.96 | 2019-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $414.31 | 2020-2025 | Odomzo, Blu-U |
| Amgen INC. | $341.77 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $264.01 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $239.79 | 2022-2025 | Libtayo, Dupixent |
| E.R. Squibb & Sons, L.L.C. | $238.28 | 2023-2024 | Sotyktu |
| Leo Pharma INC. | $222.56 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Sanofi-Aventis U.S. LLC | $189.94 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Biofrontera INC. | $120.76 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Journey Medical Corporation | $76.69 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $66.33 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $60.95 | 2024-2025 | Zoryve |
| Allergan, INC. | $55.50 | 2019 | |
| Prugen, INC. Pharmaceuticals | $48.36 | 2019 | |
| Nobelpharma America, LLC | $43.44 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.45 | 2022-2025 | Spevigo |
| Almirall LLC | $34.51 | 2019 | |
| Mayne Pharma Commercial LLC | $30.98 | 2019 | |
| Genentech USA, INC. | $30.78 | 2019-2020 | |
| Organon LLC | $27.09 | 2025 | Vtama |
| Strata Skin Sciences, INC. | $23.92 | 2024 | Xtrac |
| Celgene Corporation | $23.17 | 2019 | |
| Cipher Pharmaceuticals US LLC | $22.50 | 2025 | Spinosad, Natroba |
| Aclaris Therapeutics, INC. | $20.54 | 2019 | |
| Kyowa Kirin, INC. | $19.33 | 2024 | Poteligeo |
| Epi Health, LLC | $18.87 | 2020 | |
| Vyne Pharmaceuticals INC. | $13.11 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.